These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 11442640)

  • 1. Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A.
    Mauser-Bunschoten EP; van der Bom JG; Bongers M; Twijnstra M; Roosendaal G; Fischer K; van den Berg HM
    Haemophilia; 2001 Jul; 7(4):364-8. PubMed ID: 11442640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates.
    Scharrer I; Bray GL; Neutzling O
    Haemophilia; 1999 May; 5(3):145-54. PubMed ID: 10444280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates.
    Zanon E; Zerbinati P; Girolami B; Bertomoro A; Girolami A
    Blood Coagul Fibrinolysis; 1999 Apr; 10(3):117-20. PubMed ID: 10357004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of inhibitor development in severe haemophilia A children treated with cryoprecipitate and low-dose immune tolerance induction.
    ElAlfy MS; Tantawy AA; Ahmed MH; Abdin IA
    Haemophilia; 2000 Nov; 6(6):635-8. PubMed ID: 11122388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.
    Hassan S; Cannavò A; Gouw SC; Rosendaal FR; van der Bom JG
    J Thromb Haemost; 2018 Jun; 16(6):1055-1068. PubMed ID: 29665204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.
    Addiego J; Kasper C; Abildgaard C; Hilgartner M; Lusher J; Glader B; Aledort L
    Lancet; 1993 Aug; 342(8869):462-4. PubMed ID: 8102429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of inhibitors in haemophiliacs. A review of the literature.
    Scharrer I; Neutzling O
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):753-8. PubMed ID: 8292725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies.
    Volkers P; Hanschmann KM; Calvez T; Chambost H; Collins PW; Demiguel V; Hart DP; Hay CRM; Goudemand J; Ljung R; Palmer BP; Santagostino E; van Hardeveld EM; van den Berg M; Keller-Stanislawski B
    Haemophilia; 2019 May; 25(3):398-407. PubMed ID: 31066174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.
    Gouw SC; van der Bom JG; Auerswald G; Ettinghausen CE; Tedgård U; van den Berg HM
    Blood; 2007 Jun; 109(11):4693-7. PubMed ID: 17218379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A.
    Mancuso ME; Mannucci PM; Rocino A; Garagiola I; Tagliaferri A; Santagostino E
    J Thromb Haemost; 2012 May; 10(5):781-90. PubMed ID: 22452823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.
    Calvez T; Chambost H; d'Oiron R; Dalibard V; Demiguel V; Doncarli A; Gruel Y; Huguenin Y; Lutz P; Rothschild C; Vinciguerra C; Goudemand J;
    Haematologica; 2018 Jan; 103(1):179-189. PubMed ID: 29025913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate.
    Peerlinck K; Arnout J; Di Giambattista M; Gilles JG; Laub R; Jacquemin M; Saint-Remy JM; Vermylen J
    Thromb Haemost; 1997 Jan; 77(1):80-6. PubMed ID: 9031454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product.
    Yee TT; Williams MD; Hill FG; Lee CA; Pasi KJ
    Thromb Haemost; 1997 Sep; 78(3):1027-9. PubMed ID: 9308748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
    Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
    Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United Kingdom.
    Mathias MC; Collins PW; Palmer BP; Chalmers E; Alamelu J; Richards M; Will A; Hay CRM;
    Haemophilia; 2018 Nov; 24(6):896-901. PubMed ID: 30004617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products.
    Rota M; Cortesi PA; Steinitz-Trost KN; Reininger AJ; Gringeri A; Mantovani LG
    Blood Coagul Fibrinolysis; 2017 Dec; 28(8):627-637. PubMed ID: 28678027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate.
    Peerlinck K; Arnout J; Gilles JG; Saint-Remy JM; Vermylen J
    Thromb Haemost; 1993 Feb; 69(2):115-8. PubMed ID: 8456422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.
    Gensana M; Altisent C; Aznar JA; Casaña P; Hernández F; Jorquera JI; Magallón M; Massot M; Puig L
    Haemophilia; 2001 Jul; 7(4):369-74. PubMed ID: 11442641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors incidence rate in Czech previously untreated patients with haemophilia A has not increased since introduction of recombinant factor VIII treatment in 2003.
    Blatny J; Komrska V; Blazek B; Penka M; Ovesna P;
    Blood Coagul Fibrinolysis; 2015 Sep; 26(6):673-8. PubMed ID: 25886834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution.
    Rocino A; Papa ML; Salerno E; Capasso F; Miraglia E; de Biasi R
    Haemophilia; 2001 Jan; 7(1):33-8. PubMed ID: 11136378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.